This technology uses peripheral blood biomarkers—NfL for brain injury, CCL11 for stress-induced alcohol use, Nectin-4 for opioid/ketamine addiction, and MPO for alcohol relapse. These markers provide objective, quantifiable tools to improve diagnosis and treatment in addiction medicine. The approach is innovative, clinically valuable, and holds strong market and industrial potential.

Addiction diagnosis often uses blood or urine tests to detect substance use, but these are error-prone and mainly for legal use. A better approach focuses on patient needs—assessing brain and body damage from long-term use. Reliable biomarkers reflecting physical tolerance can help clinicians offer more precise, personalized care.

This technology supports clinical diagnostics, precision medicine, and telehealth by enabling objective assessment of addiction and brain injury. Biomarkers can be integrated into platforms like SIMOA and ELLA to develop new tools. It aids personalized care and offers value in public health and clinical training.